• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人膀胱肌层浸润性尿路上皮细胞癌:多向分化与转移能力

Muscle-invasive urothelial cell carcinoma of the human bladder: multidirectional differentiation and ability to metastasize.

作者信息

Domanowska Ewa, Jozwicki Wojciech, Domaniewski Jan, Golda Ryszard, Skok Zdzislaw, Wiśniewska Halina, Sujkowska Renata, Wolski Zbigniew, Jozwicka Grazyna

机构信息

Department of Clinical Pathology, The Ludwik Rydygier Collegium Medicum in Bydgoszcz Nicolaus Copernicus University in Torun, Bydgoszcz, Poland.

出版信息

Hum Pathol. 2007 May;38(5):741-6. doi: 10.1016/j.humpath.2006.11.001. Epub 2007 Feb 15.

DOI:10.1016/j.humpath.2006.11.001
PMID:17306328
Abstract

Few published studies have addressed the correlation between multidirectional differentiation in muscle-invasive bladder cancer and its ability to metastasize. We demonstrated that histologic differentiation within a single tumor affects lymph node metastasis. We examined cystectomy specimens from 93 bladder tumors and 1085 lymph nodes. In this study, urothelial cell carcinomas (UCCs) with divergent differentiation, excluding pure divergent patterns such as squamous cell carcinoma and adenocarcinoma that tend toward a distinct biologic behavior, were subjected to histopathologic estimation. The positive lymph node ratio increased with the nonconventional differentiation number (NDN) within a tumor from 8.7% for an NDN of 0 (pure conventional UCCs) to 35.5% for an NDN of 2 or higher (mixed conventional and nonconventional [NC] UCCs showing >2 NC patterns). The positive lymph node number (PLN) was more than twice as high for an NDN of 3 or higher as compared with cases with an NDN of 0. Lymph node positivity (LP) was associated with the presence of micropapillary, lymphoma-like, plasmacytoid, giant cell, or clear cell-type tumors, and increasing PLN was associated with the presence of glandular, nested, lymphoma-like, plasmacytoid, or undifferentiated types in the primary tumor. By multivariate analysis, NDN status was determined to be an independent predictor of PLN (P = .032). Tumor stage had impact on LP (P = .002); however, in cases with a PLN of 4 or higher, the NDN became the only predictor of further dissemination (P = .016). No significant tumor grade impact on LP or PLN was found. Our results indicate that NC differentiation in the primary tumor is a good predictor of lymph node dissemination.

摘要

很少有已发表的研究探讨肌层浸润性膀胱癌的多向分化与其转移能力之间的相关性。我们证明了单个肿瘤内的组织学分化会影响淋巴结转移。我们检查了93例膀胱肿瘤和1085个淋巴结的膀胱切除标本。在本研究中,对具有不同分化的尿路上皮细胞癌(UCC)进行组织病理学评估,不包括倾向于独特生物学行为的纯不同模式,如鳞状细胞癌和腺癌。肿瘤内的阳性淋巴结比例随非常规分化数量(NDN)增加,NDN为0(纯常规UCC)时为8.7%,NDN为2或更高(显示>2种NC模式的混合常规和非常规[NC]UCC)时为35.5%。NDN为3或更高时的阳性淋巴结数量(PLN)是NDN为0时病例的两倍多。淋巴结阳性(LP)与微乳头、淋巴瘤样、浆细胞样、巨细胞或透明细胞型肿瘤的存在相关,而PLN增加与原发性肿瘤中腺管样、巢状、淋巴瘤样、浆细胞样或未分化类型的存在相关。通过多变量分析,确定NDN状态是PLN的独立预测因子(P = .032)。肿瘤分期对LP有影响(P = .002);然而,在PLN为4或更高的病例中,NDN成为进一步扩散的唯一预测因子(P = .016)。未发现肿瘤分级对LP或PLN有显著影响。我们的结果表明,原发性肿瘤中的NC分化是淋巴结扩散的良好预测指标。

相似文献

1
Muscle-invasive urothelial cell carcinoma of the human bladder: multidirectional differentiation and ability to metastasize.人膀胱肌层浸润性尿路上皮细胞癌:多向分化与转移能力
Hum Pathol. 2007 May;38(5):741-6. doi: 10.1016/j.humpath.2006.11.001. Epub 2007 Feb 15.
2
Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors.膀胱肌层浸润性尿路上皮癌中Her-2/neu过表达:原发性和转移性肿瘤的预后意义及比较分析
Clin Cancer Res. 2001 Aug;7(8):2440-7.
3
Invasive micropapillary urothelial carcinoma of the bladder.膀胱浸润性微乳头状尿路上皮癌。
Hum Pathol. 2010 Aug;41(8):1159-64. doi: 10.1016/j.humpath.2009.11.018. Epub 2010 Apr 8.
4
Usefulness of histologic homogeneity estimation of muscle-invasive urinary bladder cancer in an individual prognosis: a mapping study.组织学同质性评估在肌层浸润性膀胱癌个体预后中的作用:一项图谱研究
Urology. 2005 Nov;66(5):1122-6. doi: 10.1016/j.urology.2005.06.134.
5
Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection.具有不同组织学分化(混合组织学特征)的尿路上皮癌在经尿道切除术中被检测到时,提示存在局部晚期膀胱癌。
Urology. 2007 Jul;70(1):69-74. doi: 10.1016/j.urology.2007.03.033.
6
Urachal carcinomas of the nonglandular type: salient features and considerations in pathologic diagnosis.非腺样脐尿管癌:病理诊断中的显著特征和注意事项。
Am J Surg Pathol. 2012 Mar;36(3):432-42. doi: 10.1097/PAS.0b013e31823fe49c.
7
Clonal origin of lymph node metastases in bladder carcinoma.膀胱癌淋巴结转移的克隆起源
Cancer. 2005 Nov 1;104(9):1901-10. doi: 10.1002/cncr.21466.
8
Plasmacytoid urothelial carcinoma of the bladder.膀胱浆细胞样尿路上皮癌
Hum Pathol. 2009 Jul;40(7):1023-8. doi: 10.1016/j.humpath.2009.01.001. Epub 2009 Mar 17.
9
Divergent differentiation in urothelial carcinoma and other bladder cancer subtypes with selected mimics.尿路上皮癌及其他膀胱癌亚型与特定模拟物的分化差异。
Histopathology. 2009 Jun;54(7):885-900. doi: 10.1111/j.1365-2559.2008.03167.x. Epub 2008 Oct 30.
10
Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival.膀胱癌根治性膀胱切除术后软组织切缘阳性与癌症特异性生存
J Urol. 2007 Dec;178(6):2308-12; discussion 2313. doi: 10.1016/j.juro.2007.08.023. Epub 2007 Oct 22.

引用本文的文献

1
Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 1: General Issues and Marker Expression.我们是否准备好在临床实践中实施膀胱癌的分子亚型分类?第 1 部分:一般问题和标志物表达。
Int J Mol Sci. 2022 Jul 15;23(14):7819. doi: 10.3390/ijms23147819.
2
Bladder urothelial carcinoma producing insulin-like growth factor II: A case report.产生胰岛素样生长因子II的膀胱尿路上皮癌:一例报告。
IJU Case Rep. 2018 Sep 20;1(1):9-12. doi: 10.1002/iju5.12018. eCollection 2018 Nov.
3
Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study.
新辅助化疗和根治性膀胱切除术治疗膀胱癌伴鳞癌变异患者的不良癌症特异性生存:一项多机构研究。
Clin Genitourin Cancer. 2020 Oct;18(5):e543-e556. doi: 10.1016/j.clgc.2020.01.007. Epub 2020 Feb 8.
4
Tissue Profile of CDK4 and STAT3 as Possible Innovative Therapeutic Targets in Urinary Bladder Cancer.细胞周期蛋白依赖性激酶4(CDK4)和信号转导与转录激活因子3(STAT3)在膀胱癌中的组织表达谱:潜在的创新治疗靶点
Asian Pac J Cancer Prev. 2020 Feb 1;21(2):547-554. doi: 10.31557/APJCP.2020.21.2.547.
5
Impact of squamous and/or glandular differentiation on recurrence and progression following transurethral resection for non-muscle invasive urothelial carcinoma of bladder.膀胱非肌层浸润性尿路上皮癌经尿道切除术后鳞状和/或腺性分化对复发和进展的影响
Oncol Lett. 2017 Sep;14(3):3522-3528. doi: 10.3892/ol.2017.6581. Epub 2017 Jul 15.
6
Adjuvant treatment following radical cystectomy for muscle-invasive urothelial carcinoma and variant histologies: Is there a role for radiotherapy?肌层浸润性尿路上皮癌及变异组织学类型行根治性膀胱切除术后的辅助治疗:放射治疗有作用吗?
ESMO Open. 2017 Mar 7;1(6):e000123. doi: 10.1136/esmoopen-2016-000123. eCollection 2016.
7
Trimodality therapy in variant urothelial carcinoma: choose wisely.变异型尿路上皮癌的三联疗法:明智选择。
Transl Androl Urol. 2017 Apr;6(2):322-325. doi: 10.21037/tau.2017.03.59.
8
The Response of Variant Histology Bladder Cancer to Intravesical Immunotherapy Compared to Conventional Cancer.与传统癌症相比,变异组织学膀胱癌对膀胱内免疫疗法的反应。
Front Oncol. 2016 Mar 15;6:43. doi: 10.3389/fonc.2016.00043. eCollection 2016.
9
Changes in Immunogenicity during the Development of Urinary Bladder Cancer: A Preliminary Study.膀胱癌发生发展过程中的免疫原性变化:一项初步研究。
Int J Mol Sci. 2016 Feb 25;17(3):285. doi: 10.3390/ijms17030285.
10
Frequency of CD4+CD25+Foxp3+ cells in peripheral blood in relation to urinary bladder cancer malignancy indicators before and after surgical removal.手术切除前后外周血中CD4+CD25+Foxp3+细胞频率与膀胱癌恶性指标的关系
Oncotarget. 2016 Mar 8;7(10):11450-62. doi: 10.18632/oncotarget.7199.